Zoetis Inc.(ZTS)Company Profile & BusinessNYSE
Business, leadership and ownership
Company Profile
Business overview, scale, and footprint
Business Overview
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics.
In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.
Insider Transactions
Open-market activity and option exercises
Insider Activity Summary
Insider trading activity for Zoetis Inc. (ZTS) between Jun 28, 2024 and Aug 7, 2026 consists of 93 total transactions. Among these, company executives and board members conducted 93 buys (totaling 254,487 shares) and 0 sells (totaling 0 shares). This activity resulted in a net change of 254,487 shares, reflecting net buying interest with an estimated net acquisitions value of $7.64M.
93 insider transactions found. Showing 10 of 93 transactions.
| Insider Name | Relation to Company | Shares Changed | Price | Transaction Date |
|---|---|---|---|---|
| D AMELIO FRANK A | Director | 6,650 | N/A | Aug 7, 2026 |
| MCCALLISTER MICHAEL B | Director | 1,209 | N/A | Jun 10, 2026 |
| STETTER MARK | Director | 1,572 | N/A | May 21, 2026 |
| PARENT LOUISE M | Director | 12,130 | N/A | May 20, 2026 |
| BISARO PAUL M. | Director | 2,000 | $0.15 | May 13, 2026 |
| D AMELIO FRANK A | Director | 6,650 | $0.50 | May 13, 2026 |
| DAMELIO FRANK A | Director | 6,650 | $75.39 | May 13, 2026 |
| Bisaro Paul | Director | 2,000 | $75.88 | May 13, 2026 |
| MCCALLISTER MICHAEL B | Director | 3,000 | $77.76 | May 11, 2026 |
| ESCH KEVIN PH.D. | Officer | 259 | N/A | Apr 30, 2026 |
Explore More Analysis for ZTS
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.